Generic and biosimilar launches don’t happen on a calendar—they happen when exclusivity breaks.
In formulary strategy, the difference between “early” and “too late” can be measured in weeks, not quarters. And those weeks are often determined by one t…

Most people read a drug pipeline after it’s already public.
The smarter question is: what were the companies doing before they published it—and what does that imply for pricing, competition, and timing?
That’s the core idea behind competitive forecasti…

20 Years on Paper: The Real Guide to Drug Patent Duration in the United States
Most people think drug patent life is simple: file today, expire 20 years later. In practice, that “20 years” is often more like a starting gun than a finish line—and the di…

Pick the Right Patent—or Leave Billions on the Table: The One-Patent Rule and PTE Selection Strategy
In pharma, the difference between a blockbuster and a bust often isn’t the science. It’s the paperwork.
A single misstep in patent selection—or a failu…

South America’s drug patent landscape isn’t “one market.” It’s a patchwork—and the difference between winning and losing in pharma strategy is often a matter of jurisdictional detail.
That’s the core takeaway from DrugPatentWatch’s country-by-country b…

Most 505(b)(2) strategies fail before the first filing—because teams treat “regulatory pathway” like a checkbox, not a business model.
If you’re a CDMO, specialty lab, or service provider supporting 505(b)(2) follow-on drugs, the opportunity is real—bu…

Pharma’s “wall” isn’t a single patent. It’s a stack.
If you think generic competition is delayed because of one blockbuster patent, you’re missing the real playbook. The modern strategy—especially in high-value therapeutic areas—is to build a layered e…

India’s Drug Patent Clock: The “Definitive” Reality Behind How Long Protection Really Lasts
If you’re a pharma executive, investor, or in-house counsel, you already know the headline: patent protection is time-limited. But in India, the real story is l…

The $467 Billion Generic Drug Race Is Really a Timing Game—Here’s the Hatch-Waxman Playbook Behind It
If you think the generic drug market is just about “who files first,” you’re missing the real competitive edge: who can win the patent clock.
A new an…